Your Article Summary
See Latest ArticlesBortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial
Leukemia and Lymphoma, 07/01/09
Chanan-Khan A et al. - Fatigue and sensory neuropathy were the most common side effects noted. The authors observe that VDT is an effective steroid-free regimen with ability to induce durable remission even in patients with refractory myeloma.
Related Articles
Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
Journal of Clinical Oncology, 11/20/09
Relevance Score: 90%
Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma
Blood, 11/02/09
Relevance Score: 89%
Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
Annals of Oncology, 10/30/09
Relevance Score: 89%
Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
Journal of Clinical Oncology, 10/02/09
Relevance Score: 89%
A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors
Cancer Chemotherapy and Pharmacology, 10/01/09
Relevance Score: 89%
Today in Myeloproliferative Dz...keeping you current
Receive free subspecialty "5-minute updates" via email
Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia
Journal of Clinical Oncology, 12/20/09
Targeting the Fanconi Anemia/BRCA Pathway Circumvents Drug Resistance in Multiple Myeloma
Cancer Research, 12/20/09
High-resolution single-nucleotide polymorphism array-profiling in myeloproliferative neoplasms identifies novel genomic aberrations
Haematologica, 12/19/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase
Journal of Clinical Oncology, 12/20/09
Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
Journal of Clinical Oncology, 12/20/09
Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia
Journal of Clinical Oncology, 12/20/09